Engineered human IL-21 cytokines and methods for using the same
US12012441B2 · kind B2 · utility
0Cited by
40References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2023 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | Apr 20, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/54
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor α chain (“ortho-IL-21Rα”) that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21Rα, wherein the ortho-IL-21Rα binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.